Handelsavisen
prelaunch
Companies ›Healthcare ›REPL.MKE
RE
REPL.MKE — — Pharmaceuticals

Replek AD Skopje

$16 000,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
3,12 %
Op margin
8,1 %
ROE
—
Net margin
5,9 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Replek AD Skopje is a pharmaceutical company that develops, produces, and distributes prescription and over-the-counter medicines, primarily in the Balkans and Eastern Europe.

Business. Replek AD Skopje (REPL.MKE) is a pharmaceutical company headquartered in Skopje that operates within the Pharmaceuticals & Medical Research industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments and geographic revenue mix are not disclosed. The company is listed under the ticker REPL.MKE.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
HOLD8 analysts
3 buy4 hold1 sell
Avg 12m price target9,27

Analyst recommendations

8 analysts · consensus Hold
Buy3
Hold4
Sell1
12-month price target
9,27
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
8 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning REPL.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to REPL.MKE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Replek AD Skopje (REPL.MKE) is a pharmaceutical company headquartered in Skopje that operates within the Pharmaceuticals & Medical Research industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments and geographic revenue mix are not disclosed. The company is listed under the ticker REPL.MKE.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Replek AD Skopje has a capital structure with 259,200 basic and diluted shares outstanding, indicating no dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company reported a gross profit of MKD 198.78 million and an operating income of MKD 31.45 million, translating to a gross margin of 51.25% and an operating margin of 8.11%. These figures are consistent with industry norms for pharmaceutical firms, which typically maintain high gross margins due to the capital-intensive nature of R&D and production.

    Geographically, Replek's revenue is concentrated in the Balkans and Eastern Europe, with no disclosed segment breakdown. This regional concentration may expose the company to regulatory and economic volatility in these markets, particularly in light of geopolitical tensions in the region.

    Looking ahead, the company's growth trajectory is constrained by limited financial disclosure. While the current fiscal year's revenue of MKD 387.91 million provides a baseline, there are no disclosed projections for the next fiscal year. The absence of detailed guidance limits visibility into future performance.

    Risk factors include the inability to assess liquidity risk and the lack of detailed financial disclosures. The company has not issued any recent public filings or transcripts that would clarify its capital structure or strategic direction.

    Recent events include the absence of notable filings or transcripts, which limits the ability to assess management's strategic direction or financial health. The company has not issued any public statements or guidance that would indicate a shift in business strategy or financial outlook.

    Key takeaways
    • Replek AD Skopje operates in the pharmaceutical industry with a strong gross margin of 51.25%.
    • The company has no dilution pressure from share-based compensation or convertible instruments.
    • Liquidity risk could not be assessed due to the absence of balance-sheet inputs.
    • Revenue is concentrated in the Balkans and Eastern Europe, exposing the company to regional economic and regulatory risks.
    • Limited financial disclosure restricts visibility into the company's future growth trajectory.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $16 000,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries3
    EX21:7026290a8e7dEX21:7026290a8e7dSubsidiarie97%
    EX21:817ccb136d6eEX21:817ccb136d6eSubsidiarie97%
    EX21:d41edc4d228aEX21:d41edc4d228aSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 62 %
    EPS
    Consensus EPS
    -2,21
    Predicted surprise
    -0,07
    Beat probability
    62 %
    Analysts
    8
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    revision ratio 0,34 · as of 2026-07-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$2,00
    Mean$9,27
    Median$9,00
    High$16,00
    Spot$16 000,00
    −99.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    Op Margin8,1 %Above median
    Net Margin5,9 %Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 087 860 sh14 grants14 insiders
    • BAKER BROS. ADVISORS LPDirector, 10% owner · Non-Qualified Stock Option (right to buy)uy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • Sarchi ChristopherChief Commercial Officer · Employee Stock Option (right to buy) → Common StockAcquired 75 000 @ $7,61grant · 2026-04-01
    • Astley-Sparke PhilipDirector · Stock Option (right to buy) → Common StockAcquired 75 000 @ $7,61grant · 2026-04-01
    • Weinand DieterDirector · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • Hill Emily LuisaChief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 75 000 @ $7,61grant · 2026-04-01
    • Peeples-Dyer VelekaDirector · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • SLATTERY JOSEPH PDirector · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • Pucci PaoloDirector · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • Dhingra KapilDirector · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • Patel SushilDirector, Chief Executive Officer · Employee Stock Option (right to buy) → Common StockAcquired 376 860 @ $7,61grant · 2026-04-01
    • Schwendenman AndrewChief Accounting Officer · Employee Stock Option (right to buy) → Common StockAcquired 55 000 @ $7,61grant · 2026-04-01
    • Balachandran MadhavanDirector · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01
    • Xynos KonstantinosChief Medical Officer · Employee Stock Option (right to buy) → Common StockAcquired 75 000 @ $7,61grant · 2026-04-01
    • Oliger Christy J.Director · Stock Option (right to buy) → Common StockAcquired 44 500 @ $7,61grant · 2026-04-01

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Replek AD Skopje Market data — financials · 2026-05-29

    Ownership & reference

    Leadership

    • Danica ZimbakovaMember of the Management Board
    • Dusan PecovskiMember of the Management Board
    • Liljana MakraduliMember of the Management Board

    Insider activity

    Net selling0 buys · 8 sellsnet -$637K6 insiders · last 365d
    • Sarchi ChristopherChief Commercial Officer · Common StockSold 12 000 @ $9,24$111K · 2026-06-01
    • Schwendenman AndrewChief Accounting Officer · Common StockSold 7 894 @ $5,08$40K · 2026-05-18
    • Sarchi ChristopherChief Commercial Officer · Common StockSold 8 626 @ $5,08$44K · 2026-05-18
    • Xynos KonstantinosChief Medical Officer · Common StockSold 14 023 @ $5,08$71K · 2026-05-18
    • Patel SushilDirector, Chief Executive Officer · Common StockSold 37 324 @ $5,08$190K · 2026-05-18
    • Hill Emily LuisaChief Financial Officer · Common StockSold 7 812 @ $5,08$40K · 2026-05-18
    • Astley-Sparke PhilipDirector · Common StockSold 17 657 @ $5,08$90K · 2026-05-18
    • Sarchi ChristopherChief Commercial Officer · Common StockSold 6 500 @ $8,01$52K · 2026-04-02
    • Sarchi ChristopherChief Commercial Officer · Common StockOther 50 000 · 2026-04-01
    • Astley-Sparke PhilipDirector · Common StockOther 50 000 · 2026-04-01
    • Xynos KonstantinosChief Medical Officer · Common StockOther 50 000 · 2026-04-01
    • Schwendenman AndrewChief Accounting Officer · Common StockOther 36 667 · 2026-04-01
    • Patel SushilDirector, Chief Executive Officer · Common StockOther 251 240 · 2026-04-01
    • Hill Emily LuisaChief Financial Officer · Common StockOther 50 000 · 2026-04-01
    • Astley-Sparke PhilipDirector · Common StockOther 25 000 · 2026-02-18
    • Patel SushilDirector, Chief Executive Officer · Common StockOther 200 000 · 2025-12-19
    • Xynos KonstantinosChief Medical Officer · Common StockOther 60 000 · 2025-12-19

    Short positioning

    23.7Mshares short-0.1% vs prior
    9.44days to cover
    55.8%short of daily vol
    3.2Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    REPL.MKECanonical
    — · USD

    Intel & risk

    PredictorBeat prob62 %Surprise-0,07Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown
    Relationship graph
    REPLEX21:702EX21:817EX21:d41Pharmaceutical
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Operating cash flow (annual): USD -280.34MUnknown
    • Total operating expenses (annual): USD 319.92MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -3Unknown
    • Operating income (annual): USD -319.92MUnknown
    • Pre-tax income (annual): USD -314.49MUnknown
    • R&D expense (annual): USD 221.18MUnknown
    • Net income (annual): USD -313.94MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -3Unknown
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 3.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 5.60xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.58xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -28.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -56.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -44.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 1.5%Derived (calculated)
    • Long-term debt (annual): USD 47.63MSEC XBRL filing
    • Cash & equivalents (annual): USD 122.95MSEC XBRL filing
    • Shareholders' equity (annual): USD 210.54MSEC XBRL filing
    • Current liabilities (annual): USD 50.09MSEC XBRL filing
    • Shares outstanding (annual): 79.63MSEC XBRL filing
    • Total liabilities (annual): USD 123.05MSEC XBRL filing
    • Current assets (annual): USD 280.35MSEC XBRL filing
    • Total assets (annual): USD 333.59MSEC XBRL filing
    • Operating cash flow (YoY) (2025-03-31 vs 2024-03-31): -3.7%Derived (calculated)
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-07-02 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-02 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-07-02EVENTQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-25 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-06-25EVENTQ2 2026 earnings (expected) estimated date
    2026-06-01 00:00 UTCINSIDER1 insider transaction — 2026-06 · net sell $111k
    2026-06-01INSIDERSarchi Christopher sold 12.0k sh — Chief Commercial Officer ~$111k
    2026-05-29FILINGFORM 8-K →
    2026-05-18 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $474k
    2026-05-18INSIDERSchwendenman Andrew sold 7.9k sh — Chief Accounting Officer ~$40k
    2026-05-18INSIDERSarchi Christopher sold 8.6k sh — Chief Commercial Officer ~$44k
    2026-05-18INSIDERXynos Konstantinos sold 14.0k sh — Chief Medical Officer ~$71k
    2026-05-18INSIDERPatel Sushil sold 37.3k sh — Director, Chief Executive Officer ~$190k
    2026-05-18INSIDERHill Emily Luisa sold 7.8k sh — Chief Financial Officer ~$40k
    2026-05-18INSIDERAstley-Sparke Philip sold 17.7k sh — Director ~$90k
    2026-04-13FILINGFORM 8-K →
    2026-04-02 00:00 UTCINSIDER21 insider transactions — 2026-04 14 derivative
    2026-04-02INSIDERSarchi Christopher sold 6.5k sh — Chief Commercial Officer ~$52k
    2026-04-01INSIDERSarchi Christopher transacted 50.0k sh — Chief Commercial Officer
    2026-04-01INSIDERAstley-Sparke Philip transacted 50.0k sh — Director
    2026-04-01INSIDERXynos Konstantinos transacted 50.0k sh — Chief Medical Officer
    2026-04-01INSIDERSchwendenman Andrew transacted 36.7k sh — Chief Accounting Officer
    2026-04-01INSIDERPatel Sushil transacted 251.2k sh — Director, Chief Executive Officer
    2026-04-01INSIDERHill Emily Luisa transacted 50.0k sh — Chief Financial Officer
    2026-04-01INSIDERBAKER BROS. ADVISORS LP acquired 44.5k sh Non-Qualified Stock Option (right to buy)uy) — Director, 10% owner
    2026-04-01INSIDERSarchi Christopher acquired 75.0k sh Employee Stock Option (right to buy) — Chief Commercial Officer
    2026-04-01INSIDERWeinand Dieter acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERSchwendenman Andrew acquired 55.0k sh Employee Stock Option (right to buy) — Chief Accounting Officer
    2026-04-01INSIDERPatel Sushil acquired 376.9k sh Employee Stock Option (right to buy) — Director, Chief Executive Officer
    2026-04-01INSIDERDhingra Kapil acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERPucci Paolo acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERAstley-Sparke Philip acquired 75.0k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERSLATTERY JOSEPH P acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERHill Emily Luisa acquired 75.0k sh Employee Stock Option (right to buy) — Chief Financial Officer
    2026-04-01INSIDERBalachandran Madhavan acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERPeeples-Dyer Veleka acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDEROliger Christy J. acquired 44.5k sh Stock Option (right to buy) — Director
    2026-04-01INSIDERXynos Konstantinos acquired 75.0k sh Employee Stock Option (right to buy) — Chief Medical Officer
    Showing the 40 most recent of 55 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage